| 2026-08-03 | United States | Settlement | Sandoz Agrees to $450 Million Settlement With 43 US States Over Generic Drug Antitrust Claims Pharmaceutical Executive | $450 Million |
| 2025-10-24 | United States | Other | In Re Novartis Pharmaceuticals Corporation Texas Supreme Court | — |
| 2024-12-27 | United States | Other | Camburn v. Novartis Pharmaceuticals Corporation Court of Appeals for the Second Circuit | — |
| 2020-07-01 | United States | Settlement | Acting Manhattan U.S. Attorney Announces $678 Million Settlement Of Fraud Lawsuit Against Novartis Pharmaceuticals For Operating Sham Speaker Programs Through Which It Paid Over $100 Million To Doctor U.S. Department of Justice | $678 Million |
| 2020-07-01 | United States | Settlement | Novartis Agrees to Pay Over $51 Million to Resolve Allegations that It Paid Kickbacks Through Co-Pay Foundations U.S. Department of Justice | $51 Million / $51.25 million |
| 2020-06-25 | United States | Settlement | Novartis Hellas S.A.C.I. and Alcon Pte Ltd Agree to Pay over $233 Million Combined to Resolve Criminal FCPA Cases U.S. Department of Justice | $233 Million |
| 2020-06-25 | United States | Settlement | Novartis AG and Subsidiaries to Pay $345 Million to Resolve Foreign Corrupt Practices Act Cases U.S. Department of Justice | $345 Million |
| 2020 | United States | Settlement | In June 2020, Novartis reached settlements with the US Department of Justice (DOJ) and the US Securities and Exchange Commission (SEC) resolving all Foreign Corrupt Practices Act (FCPA) investigations Wikipedia: Novartis（Controversies and criticism） + 1 more reports | US$233.9 million / US$112.8 million |
| 2020 | United States | Settlement | In July 2020, Novartis Pharmaceuticals Corporation agreed to pay $642 million to settle allegations under the False Claims Act involving improper payments to patients and physicians. Of the total, $59 Wikipedia: Novartis（Controversies and criticism） + 1 more reports | $642 million / $591 million / $51.25 million |
| 2019 | United States | Other | Having already received approval for Zolgensma in May 2019, on 28 June AveXis (a Novartis company) voluntarily disclosed to the FDA that some data previously submitted to the agency as part of the Bio Wikipedia: Novartis（Controversies and criticism） | — |
| 2018 | European Union | Filed / under investigation | In January 2018, Novartis began being investigated by US and Greek authorities for allegedly bribing Greek public officials in the 2006–2015 period, in a scheme which included two former prime ministe Wikipedia: Novartis（Controversies and criticism） + 1 more reports | — |
| 2017-12-21 | United States | Other | T.H. v. Novartis Pharmaceuticals Corporation California Supreme Court | — |
| 2016-06-17 | United States | Filed / under investigation | United States Ex. Rel. Kelly v. Novartis Pharmaceuticals Corp. Court of Appeals for the First Circuit | — |
| 2016-03-09 | United States | Filed / under investigation | T.H v. Novartis Pharmaceuticals California Court of Appeal + 1 more reports | — |
| 2015-11-20 | United States | Settlement | Manhattan U.S. Attorney Announces $370 Million Civil Fraud Settlement Against Novartis Pharmaceuticals For Kickback Scheme Involving High-Priced Prescription Drugs, Along With $20 Million Forfeiture Of Proceeds From The Scheme U.S. Department of Justice + 1 more reports | $370 Million / $20 Million / $390 million |
| 2015-03-17 | United States | Filed / under investigation | United States ex rel. Garcia v. Novartis AG District Court, D. Massachusetts | — |
| 2015-02-27 | United States | Filed / under investigation | United States ex rel. Galmines v. Novartis Pharmaceuticals Corp. District Court, E.D. Pennsylvania | — |
| 2014-09-30 | United States | Filed / under investigation | United States ex rel. Bilotta v. Novartis Pharmaceuticals Corp. District Court, S.D. New York + 1 more reports | — |
| 2014-05-27 | United States | Filed / under investigation | Thomas Mckay v. Novartis Pharmaceutical Cor Court of Appeals for the Fifth Circuit | — |
| 2014-05-09 | United States | Filed / under investigation | Bee v. Novartis Pharmaceuticals Corp. District Court, E.D. New York | — |
| 2014-01-16 | Japan | Filed / under investigation | Novartis faces charges in Japan over promotion of valsartan to doctors BMJ | — |
| 2014-01-08 | United States | Settlement | Manhattan U.S. Attorney Simultaneously Files Additional Healthcare Fraud Claims Against Novartis Pharmaceuticals Corp. And Settles Lawsuit Against Bioscrip, Inc., In Connection With A Multimillion-Dol U.S. Department of Justice | — |
| 2013-04-26 | United States | Filed / under investigation | United States Files Complaint Against Novartis Pharmaceuticals Corp. for Allegedly Paying Kickbacks to Doctors in Exchange for Prescribing Its Drugs U.S. Department of Justice + 1 more reports | — |
| 2013-04-23 | United States | Filed / under investigation | Manhattan U.S. Attorney Files Healthcare Fraud Lawsuit Against Novartis Pharmaceuticals Corp. For Orchestrating A Multi-Million Dollar Prescription Drug Kickback Scheme U.S. Department of Justice | — |
| 2013-04-22 | United States | Judgment for company / dismissed | Stromenger v. Novartis Pharmaceuticals Corp. District Court, D. Oregon | — |
| 2013-03-28 | United States | Judgment for company / dismissed | McKay v. Novartis Pharmaceuticals Corp. District Court, W.D. Texas | — |
| 2013-02-15 | United States | Judgment for company / dismissed | Messick v. Novartis Pharmaceuticals Corp. District Court, N.D. California | — |
| 2013 | United States | Filed / under investigation | In April 2013, federal prosecutors filed two lawsuits against Novartis under the False Claims Act for off-label marketing and kickbacks; in both suits, prosecutors are seeking treble damages . The fir Wikipedia: Novartis（Controversies and criticism） | — |
| 2013 | Japan | Filed / under investigation | In the summer of 2013, two Japanese universities retracted several publications of clinical trials that purported to show that Valsartan (branded as Diovan) had cardiovascular benefits, when it was fo Wikipedia: Novartis（Controversies and criticism） | — |
| 2010-08-10 | United States | Judgment for company / dismissed | Indian Brand Farms, Inc. v. Novartis Crop Protection Inc. Court of Appeals for the Third Circuit | — |
| 2010-05-04 | United States | Settlement | Novartis Vaccines & Diagnostics to Pay More Than $72 Million to Resolve False Claims Act Allegations Concerning TOBI U.S. Department of Justice | $72 Million / $72.5 million |
| 2010 | United States | Settlement | 2010 | Novartis | $423 million | Off-label promotion, kickbacks | Trileptal | False Claims Act, FDCA Wikipedia: List of largest pharmaceutical settlements + 2 more reports | $423 million / $420 Million / $422.5 million / $185 million |
| 2010 | United States | Judgment against company | On 17 May 2010, a jury in the United States District Court for the Southern District of New York awarded $3,367,250 in compensatory damages against Novartis, finding that the company had committed sex Wikipedia: Novartis（Controversies and criticism） | $3,367,250 / $152.5 million |
| 2008 | United States | Warning letter / order | In September 2008, the US Food and Drug Administration (FDA) sent a notice to Novartis Pharmaceuticals regarding its advertising of Focalin XR, an ADHD drug, in which the company overstated its effica Wikipedia: Novartis（Controversies and criticism） | — |
| 2006-10-16 | United States | Filed / under investigation | Perry v. Novartis Pharma. Corp. District Court, E.D. Pennsylvania | — |
| 2006-08-21 | United States | Judgment for company / dismissed | Mortellite v. Novartis Crop Protection, Inc. Court of Appeals for the Third Circuit | — |
| 2005 | United States | Settlement | In 2005, federal prosecutors opened an investigation into Novartis' marketing of several drugs: Trileptal , an antiseizure drug; three drugs for heart conditions— Diovan (the company's top-selling pro Wikipedia: Novartis（Controversies and criticism） | US$422.5 million |
| 2003-02-13 | United Kingdom | Judgment for company / dismissed | Novartis was not in breach of code for “inventing” disease BMJ | — |